Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > TCRR TCR2 Therapeutics > Detailed Quotes

TCRR TCR2 Therapeutics

1.8100.0000.00%
Close 10/05 16:00 ET
1.850
+0.040+2.21%
Post Mkt Price 10/05 16:36 ET
High
1.865
Open
1.820
Turnover
256.81K
Low
1.770
Pre Close
1.810
Volume
140.81K
Market Cap
69.88M
P/E(TTM)
Loss
52wk High
8.820
Shares
38.61M
P/E(Static)
Loss
52wk Low
1.598
Float Cap
45.65M
Bid/Ask %
-60.00%
Historical High
35.860
Shs Float
25.22M
Volume Ratio
0.32
Historical Low
1.598
Dividend TTM
--
Div Yield TTM
--
P/B
0.31
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.56%
Amplitude
5.25%
Avg Price
1.823
Lot Size
1
Float Cap
45.65M
Bid/Ask %
-60.00%
Historical High
35.860
Shs Float
25.22M
Volume Ratio
0.32
Historical Low
1.598
Dividend TTM
--
P/B
0.31
Dividend LFY
--
Turnover Ratio
0.56%
Amplitude
5.25%
Avg Price
1.823
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.
CEO: Dr. Garry E. Menzel, PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...